About ImmunoVaccine (TSE:IMV)
Immunovaccine Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Rhino Resources Inc. and changed its name to Immunovaccine Inc. in September 2009. Immunovaccine Inc. was founded in 2000 and is based in Halifax, Canada.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
ImmunoVaccine (TSE:IMV) Frequently Asked Questions
What is ImmunoVaccine's stock symbol?
ImmunoVaccine trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV."
How were ImmunoVaccine's earnings last quarter?
When is ImmunoVaccine's next earnings date?
Who are some of ImmunoVaccine's key competitors?
Some companies that are related to ImmunoVaccine include Oxford BioMedica (OXB), BioTime (BTX), 22nd Century Group (XXII), Horizon Discovery (HZD), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Tiziana Life Sciences (TILS), Pfenex (PFNX), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Ergomed (ERGO), Navidea Biopharmaceuticals (NAVB), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), Actinium Pharmaceuticals (ATNM) and AmpliPhi Biosciences (APHB).
Who are ImmunoVaccine's key executives?
ImmunoVaccine's management team includes the folowing people:
- Mr. Frederic Ors, CEO & Director (Age 44)
- Dr. Gabriela Nicola Rosu M.D., Chief Medical Officer
- Mr. Leeladhar Sammatur, VP of Product Devel. & Manufacturing
- Dr. Marc Mansour Ph.D., MBA, Consultant (Age 45)
- Mr. Pierre Labbé, Chief Financial Officer (Age 53)
Has ImmunoVaccine been receiving favorable news coverage?
Media coverage about IMV stock has been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ImmunoVaccine earned a media sentiment score of 0.03 on Accern's scale. They also gave news headlines about the company an impact score of 45.70 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of ImmunoVaccine?
Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is ImmunoVaccine's stock price today?
One share of IMV stock can currently be purchased for approximately C$1.83.
How big of a company is ImmunoVaccine?
ImmunoVaccine has a market capitalization of C$255.47 million.
How can I contact ImmunoVaccine?
ImmunoVaccine's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819.
MarketBeat Community Rating for ImmunoVaccine (IMV)MarketBeat's community ratings are surveys of what our community members think about ImmunoVaccine and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
ImmunoVaccine (TSE:IMV) Analyst Ratings History
(Data available from 4/23/2016 forward)
ImmunoVaccine (TSE:IMV) Earnings History and Estimates Chart
ImmunoVaccine (TSE IMV) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/9/2018|| || || || || || || || |
|8/9/2016||Q2 2016||C($0.02)||C($0.01)||C$0.10 million||C$0.07 million||View||N/A|
|5/10/2016||Q1 2016||C($0.02)||C($0.02)||C$0.10 million||C$0.07 million||View||N/A|
|3/29/2016||Q4 2015||C($0.02)||C$0.07 million||View||N/A|
|11/12/2015||Q3 2015||C($0.02)||C$0.07 million||View||N/A|
ImmunoVaccine (TSE:IMV) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
ImmunoVaccine (TSE IMV) Insider Trading and Institutional Ownership History
ImmunoVaccine (TSE IMV) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/22/2018||Andrew J Sheldon||Director||Buy||9,500||C$1.99||C$18,905.00|
ImmunoVaccine (TSE IMV) News Headlines
|Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing|
finance.yahoo.com - April 17 at 7:42 AM
|Preclinical Data Presented at AACR Highlight the Novel Mechanism of Action Underscoring the Company’s T cell-Activating Technology|
globenewswire.com - April 16 at 3:21 PM
|Research Reports on Aurinia Pharma, Immunovaccine, IntelliPharmaCeutics International, and OrganiGram Holdings|
finance.yahoo.com - April 12 at 7:37 AM
|Immunovaccine Files Circular for Annual and Special Meeting of Shareholders|
globenewswire.com - April 5 at 9:09 AM
|Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate ...|
globenewswire.com - March 28 at 7:17 AM
|Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL|
finance.yahoo.com - March 28 at 7:17 AM
|Immunovaccine Announces Webcast of R&D Update and Investor Event|
finance.yahoo.com - March 27 at 7:19 AM
|FY2018 EPS Estimates for ImmunoVaccine Inc. Reduced by National Bank Financial (IMV)|
www.americanbankingnews.com - March 26 at 1:24 AM
|ImmunoVaccine Inc. (IMV) Director Andrew J. Sheldon Acquires 9,500 Shares|
www.americanbankingnews.com - March 22 at 1:37 PM
|Immunovaccine to Host Investor Event on April 10, 2018 in New York City - GlobeNewswire (press release)|
globenewswire.com - March 15 at 3:20 PM
|Immunovaccine to Host Investor Event on April 10, 2018 in New York City|
finance.yahoo.com - March 14 at 6:38 AM
|Immunovaccine Chief Medical Officer Dr. Gabriela Rosu to Present at the Oncology Meeting Innovations (OMI) Annual Summit on Hematologic Malignancies|
finance.yahoo.com - March 9 at 6:40 AM
|Fonds de solidarité FTQ Invests $5.75 Million In Immunovaccine Share Capital|
finance.yahoo.com - February 16 at 3:15 PM
|Immunovaccine Announces Closing of $14.375 million Bought Deal Offering with Over-allotment option exercised in full|
finance.yahoo.com - February 15 at 9:51 AM
|ImmunoVaccine Inc. (IMV) Director Buys C$30,080.00 in Stock|
www.americanbankingnews.com - February 13 at 6:46 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Insider Acquires 20,800 Shares of Stock|
www.americanbankingnews.com - February 13 at 12:30 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Director Purchases 10,000 Shares of Stock|
www.americanbankingnews.com - February 6 at 7:00 PM
|ImmunoVaccine Inc. (IMV) Director Purchases C$20,500.00 in Stock|
www.americanbankingnews.com - February 6 at 7:00 PM
|Insider Buying: ImmunoVaccine Inc. (IMV) Director Acquires 33,600 Shares of Stock|
www.americanbankingnews.com - January 26 at 12:26 PM
|Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020 - GlobeNewswire (press release)|
globenewswire.com - October 20 at 12:16 AM
|Immunovaccine Receives an Extension to the Maturity Date of its $5M Loan Until 2020|
finance.yahoo.com - October 18 at 2:33 AM
|Immunovaccine Researchers to Present Data at Two Upcoming Conferences that Demonstrate the Broad Applicability of the Company’s DepoVax™-based Programs|
finance.yahoo.com - October 5 at 9:15 AM
|New Technology Could Help Detect The Leading Cause Of Strokes|
www.baystreet.ca - September 14 at 6:26 AM
|Daily Coverage on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International|
finance.yahoo.com - September 6 at 6:23 AM
|Immunovaccine Announces Achievement of Milestones in Collaboration with Zoetis to Develop Veterinary Vaccines|
finance.yahoo.com - August 31 at 7:52 PM
|Immunovaccine to Present at 19th Annual Rodman & Renshaw ... - Nasdaq|
www.nasdaq.com - August 31 at 6:14 AM
|Immunovaccine to Present at 19th Annual Rodman & Renshaw Global Investment Conference|
finance.yahoo.com - August 31 at 6:14 AM
|ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : August 9, 2017|
finance.yahoo.com - August 9 at 8:06 PM
|ImmunoVaccine Inc. (TSE:IMV) PT Set at C$2.50 by National Bank Financial|
www.americanbankingnews.com - August 9 at 3:58 PM
|Immunovaccine Announces Financial Results for Quarter Ended June 30, 2017|
finance.yahoo.com - August 8 at 7:32 PM
|ImmunoVaccine, Inc. – Value Analysis (TORONTO:IMV) : July 31, 2017|
finance.yahoo.com - July 31 at 7:17 PM
|Insider Buying: ImmunoVaccine Inc. (TSE:IMV) Insider Buys 26,825 Shares of Stock|
www.americanbankingnews.com - July 31 at 1:25 PM
|Pierre Labbé Acquires 25,000 Shares of ImmunoVaccine Inc. (IMV) Stock|
www.americanbankingnews.com - July 21 at 1:19 PM
|ImmunoVaccine, Inc. breached its 50 day moving average in a Bullish Manner : IMV-CA : July 14, 2017|
finance.yahoo.com - July 15 at 2:51 AM
|Immunovaccine Achieves Breakthrough in Support of Developing Personalized Cancer Immunotherapies|
finance.yahoo.com - July 13 at 3:13 AM
|McCain: North Korea Is First ‘Real Test’ of Trump’s Presidency|
www.nbcnews.com - April 16 at 10:15 AM
|Syrian jets take off from air base hit by US|
abcnews.go.com - April 9 at 10:32 AM
|Fearless Florida diver pulls metal hook from shark's belly|
abcnews.go.com - March 25 at 10:38 PM
|Royal, Immunovaccine at 52-Week Highs|
www.baystreet.ca - February 6 at 5:59 PM
|Upbeat End To Quiet Week May Be In Store -- Canadian Commentary|
www.rttnews.com - February 3 at 6:27 PM
|Stocks Break Out Of Slumber Amid Jobs Momentum -- Canadian Commentary|
www.nasdaq.com - February 3 at 6:27 PM
|Appili Therapeutics Inc. Appoints Kimberly Stephens as Chief Financial Officer|
www.businesswire.com - October 3 at 5:21 PM
ImmunoVaccine (TSE:IMV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ImmunoVaccine (TSE IMV) Stock Chart for Monday, April, 23, 2018